JAK1 inhibitor with intensive immune therapy for severe aplastic anemia
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a new JAK1 inhibitor combined with strong immune-suppressing therapy for people with severe aplastic anemia that hasn't improved with standard treatments. It aims to see if this combination can help the bone marrow recover and produce healthy blood cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with severe aplastic anemia (SAA) and your bone marrow isn't making enough blood cells.
- You are 18 years or older and have an ECOG performance status of 2 or better (able to do most daily activities).
- You have already tried at least 4 months of standard immune-suppressing therapy plus a TPO-RA (a medication to boost platelets) without success, or your disease came back after treatment.
- You are not able to have or choose not to have a stem cell transplant from a donor.
- You do not have other bone marrow diseases like MDS, Fanconi anemia, or uncontrolled infections, bleeding, or certain blood test abnormalities.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral JAK1 inhibitor called golidocitnib for people with T/NK-cell lymphoma that came back after treatment or didn't respond. The drug works by blocking a signal that helps cancer cells grow.
This trial tests a new treatment to help restore blood cell production in people with aplastic anemia whose bone marrow isn't working well after a stem cell transplant or other therapies. The goal is to improve blood counts and reduce the need for transfusions or support medications.
This trial tests a new pill called jaktinib for people who develop moderate to severe acute graft-versus-host disease (aGVHD) after a stem cell transplant. The goal is to see if adding jaktinib to standard steroid therapy can better control the disease.
This trial tests the drug Golidocitinib (a JAK inhibitor) in adults with primary immune thrombocytopenia (ITP) that has not responded well to standard treatments. The goal is to see if it can safely raise and stabilize platelet counts.
This trial tests if golidocitinib, a type of JAK inhibitor, can help people with rapidly progressive interstitial lung disease (RP-ILD) — where breathing gets much worse within a month. It's for those who need steroids and other immune-suppressing drugs but haven't tried a JAK inhibitor before.
This trial tests a new oral medication called golidocitinib for people who have just been diagnosed with a specific type of T-cell lymphoma and have not had any prior treatment. The goal is to see if this JAK1 inhibitor can help control the disease.
Hear when a new Severe Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.